Skip to content
AnalystLens

Cigna Group 8-K Report, Financial Results (Jul 31, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 31, 2025
Period End
July 31, 2025
Security
CI
In the record · 2018–202610-K810-Q238-K136

CI filed 8 annual reports (10-K), 23 quarterly reports (10-Q) and 136 current reports (8-K) between 2018 and 2026.

  1. Deal closed8-K · Feb ’19Feb ’19
  2. Material agreement8-K · Apr ’21Apr ’21
  3. Leadership change8-K · Sep ’23Sep ’23
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed July 31, 2025. Cited figures are marked; the original filing is the authoritative source.

The Cigna Group (CI) reported second quarter 2025 results on July 31, 2025, with total revenues up 11% year over year to $67.2 billiona, driven mainly by Evernorth Health Services.

Shareholders' net income was $1.5 billionb, or $5.71 per diluted share, versus $5.45 a year earlier. Adjusted income from operations was $1.9 billion, or $7.20 per share, up about 1% from $6.72, and management reaffirmed full-year 2025 adjusted EPS of at least $29.60. The quality of growth is mixed.

Evernorth's adjusted pre-tax income rose 5%c and its pre-tax margin fell to 2.9% from 3.3%, reflecting a shift toward lower-margin pharmacy revenue. Cigna Healthcare's adjusted revenues fell 18%, largely because of the March 2025 divestiture of Medicare businesses to HCSC, while its MCR rose to 83.2% from 82.3% on higher stop-loss medical costs. Excluding the divestiture, Cigna Healthcare revenue grew about 7%.

Share count reduction is a meaningful driver of per-share results. Weighted average shares fell to 268.2 million from 284.1 million, and the per-share growth rate outpaced the growth in net income. Corporate and Other losses narrowed to $357 milliond from $451 million.

The SG&A expense ratio improved to 5.1% from 6.1%, which the company attributed to business mix and revenue growth. Total customer relationships were 182.2 million, with medical customers down 6% mainly because of the HCSC transaction. For investors, the key points are that the reaffirmed outlook implies limited upside from the second quarter run rate.

Medical cost pressure in Cigna Healthcare and the thin Evernorth margin are the main watch items. The filing is a furnished 8-K, so the press release is not deemed filed under the Exchange Act.

02—Key points

Key Highlights

  1. Total revenues rose 11% to $67.2 billion in Q2 2025, driven by Evernorth Health Services, including specialty pharmacy growth.
  2. Adjusted EPS was $7.20 versus $6.72 a year earlier (+7%). Adjusted income from operations rose only about 1% to $1.93 billion, and the per-share gain reflects a lower share count.
  3. GAAP shareholders' net income was $1.53 billion, or $5.71 per share, compared with $5.45 in Q2 2024.
  4. Reaffirmed full-year 2025 adjusted EPS outlook of at least $29.60, with Evernorth pre-tax adjusted income of at least $7.2 billion and Cigna Healthcare pre-tax adjusted income of at least $4.125 billion.
  5. Cigna Healthcare MCR rose to 83.2% from 82.3%, driven by higher stop-loss medical costs. The full-year MCR outlook is 83.2% to 84.2%.
  6. Evernorth pre-tax margin declined to 2.9% from 3.3%, as Pharmacy Benefit Services revenue growth of 20% outpaced profit growth of 2%.
  7. Weighted average diluted shares fell to 268.2 million from 284.1 million, and SG&A expense ratio improved to 5.1% from 6.1%.

03—Questions

Frequently Asked Questions

  1. Why did Cigna Healthcare revenue fall 18% if the business was growing?

    The decline mainly reflects the March 19, 2025 divestiture of Medicare Advantage, Medicare PDP, and related businesses to HCSC. Excluding that transaction, Cigna Healthcare adjusted revenues rose about 7%, driven by premium rate increases intended to cover higher medical costs.

  2. Is the 7% adjusted EPS growth driven by operations or by buybacks?

    Both contributed. Adjusted income from operations grew only about 1% in dollar terms, so most of the per-share increase came from the roughly 6% reduction in weighted average shares, reflecting the company's repurchase activity.

  3. Why did the company reaffirm rather than raise its 2025 outlook?

    The filing does not explicitly state the rationale. The first-half results were strong, but the company flagged higher expected stop-loss medical costs in Cigna Healthcare, and Evernorth's margin compressed. Management appears to be holding the outlook pending further visibility into medical cost trends.

  4. What are the main risks to the outlook?

    The main risks are continued medical cost pressure in Cigna Healthcare, particularly stop-loss costs, which could push the MCR toward the top of the 83.2% to 84.2% range. Evernorth's thin pre-tax margin leaves little cushion against pricing or client-mix pressure. The forward-looking statements also cite pharmacy pricing and regulatory changes.

04—Continue

← View all 8-K filings